Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) reported strong Q2 2025 results with net sales increasing 11.1% to $6.0 billion. The company achieved significant organic growth of 10.2%, driven by a 9.7% increase in unit volume and 0.5% from higher prices. Adjusted EPS grew 11.4% to $3.13, while adjusted operating income margin improved 110 basis points to 25.7%.
The MedSurg and Neurotechnology segment led growth with 17.3% increased sales to $3.8 billion, while Orthopaedics segment sales grew 2.0% to $2.2 billion. Based on strong performance, Stryker raised its 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted EPS of $13.40 to $13.60.
Inari Medical, a division of Stryker (NYSE:SYK), has launched the next-generation InThrill® Thrombectomy System, marking a significant advancement in small vessel and arteriovenous (AV) access thrombectomy procedures.
The new 8 French over-the-wire system features enhanced capabilities including increased radial force for better luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomics. The first commercial case was successfully performed on May 19, 2025, at UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra.
Stryker (NYSE:SYK) has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025. The company will release its Q2 2025 earnings press release at approximately 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.
Stryker (NYSE:SYK) has received FDA 510(k) clearance for its Incompass® Total Ankle System, designed for patients with severe ankle joint conditions. The system integrates technologies from Stryker's Inbone® and Infinity® systems into a comprehensive solution for total ankle replacement.
The innovative platform incorporates Adaptis® Boney Ingrowth Technology and is informed by data from over 85,000 CT scans and 100,000 clinical cases. Built using the SOMA platform and Prophecy Surgical Planning System, Incompass features redesigned instrumentation, improved alignment systems, and streamlined surgical workflow to enhance procedural efficiency and patient-specific care.
Stryker (NYSE:SYK) has announced its quarterly dividend declaration of $0.84 per share. The dividend will be payable on July 31, 2025, to shareholders of record as of June 30, 2025. This dividend amount represents a 5.0% increase compared to the previous year while remaining unchanged from the last quarter's distribution.
Stryker (NYSE:SYK) has announced its participation in the upcoming Bank of America Securities 2025 Global Healthcare Conference. The event will take place on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada.
Key details:
- Presenters: Preston Wells (Vice President and Chief Financial Officer) and Jason Beach (Vice President, Finance and Investor Relations)
- Presentation Time: 1:40 p.m. Pacific Time
- Access: Live webcast and replay available on www.stryker.com
- Availability: Recording will be archived on the Investor Relations page
Stryker (NYSE:SYK) has scheduled its first quarter fiscal year 2025 financial results announcement for Thursday, May 1, 2025. The company will release a press release containing summary financial information at approximately 4:05 p.m. ET, covering the quarter ending March 31, 2025.
A webcast to discuss the Q1 2025 results will be held at 4:30 p.m. ET on the same day. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available on the company's website two hours after the live call concludes.
Stryker (NYSE: SYK) has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, , which will operate under the newly formed VB Spine, . The strategic divestment aims to enhance Stryker's focus and enable investments in areas with greater innovation and growth potential.
As part of the agreement, VB Spine will have exclusive access to Mako Spine and Copilot technologies for spine procedures. Stryker maintains its presence in the spine sector through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses, along with a strategic partnership with VB Spine.
The transaction's international component will be executed in phases, with transfers to VB Spine in certain markets pending legal, regulatory, and employee consultation requirements.